Table 1.

Patient characteristics, vaccination course and clinical outcome.

ID	Prognostic scorea	Therapy before study entry	Site(s) of metastases	2.5 × 106 cells	10 × 106 cells	40 × 106 cells	Site(s) of progression	TTP (wks)	Survival (wks)
MR-1	2	—	Lung, bone	4	1	—	Bone, brainb	7	31
MR-2	1	Cytokine,c G250d	Lung, LN	4	4	2	Pleura,b boneb	23	79
MR-4	1	Cytokine, G250	Lung, LN, adrenal gland	4	4	2	Lung	35	68
MR-5	1	Cytokine	Lung	4	4	2	LN,b adrenal glandb	7	76
MR-6	2	—	Bone	—	4	2	Bone	6	18
MR-7	1	—	LN, pleura, local recurrence	—	4	2	Pleura, liverb	28	84
MR-9	2	Cytokine	Lung, pancreas	—	4	2	Pancreas, liverb	39	79
MR-10	0	Sorafenib	Lung	4	4	2	Brainb	23	55
MR-11	2	G250	Lung, LN, spinal cord	4	4	—	—	SD (7)e	17f
MR-13	1	DC, multi-peptide vaccine	Lung, LN, brain	4	4	2	Brain	33	104
MR-14	2	Multi-peptide vaccine	Lung, LN, adrenal gland	4	4	2	LN	35	107
MR-15	1	Cytokine	Lung, LN	4	4	2	—	SD (131)e	151 (alive)

TTP, time to progression; LN, lymph node; DC, dendritic cell; SD, stable disease.

^aPalmer score from 0 (very low risk) to 3 (high risk) based on performance status, number of metastatic sites and the time from first diagnosis to study entry (14).

^bNew metastases.

^cCytokine: IFN-α, IL-2, 5-fluorouracil.

^dG250: monoclonal antibody directed against carbonic anhydrase IX.

^eSD (7) and SD (131) indicate stable disease at wks 7 and 131, respectively.

^fDeath of patient MR-11, not related to therapy or disease.